272 related articles for article (PubMed ID: 23881177)
1. Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients.
Jiang M; Zhang P; Hu G; Xiao Z; Xu F; Zhong T; Huang F; Kuang H; Zhang W
Mol Cell Biochem; 2013 Nov; 383(1-2):67-75. PubMed ID: 23881177
[TBL] [Abstract][Full Text] [Related]
2. Circulating miR-21-5p and miR-126-3p: diagnostic, prognostic value, and multivariate analysis in non-small-cell lung cancer.
Soliman SE; Abdelaleem AH; Alhanafy AM; Ibrahem RAL; Elhaded ASA; Assar MFA
Mol Biol Rep; 2021 Mar; 48(3):2543-2552. PubMed ID: 33837901
[TBL] [Abstract][Full Text] [Related]
3. Serum miR-1228-3p and miR-181a-5p as Noninvasive Biomarkers for Non-Small Cell Lung Cancer Diagnosis and Prognosis.
Xue WX; Zhang MY; Rui Li ; Liu X; Yin YH; Qu YQ
Biomed Res Int; 2020; 2020():9601876. PubMed ID: 32724822
[TBL] [Abstract][Full Text] [Related]
4. [Clinical Application of Plasma miR-34b-3p and miR-302a-5p in the Diagnosis of Non-small Cell Lung Cancer].
Song Z; Zhang Z; Liu Y
Zhongguo Fei Ai Za Zhi; 2019 Apr; 22(4):216-222. PubMed ID: 31014439
[TBL] [Abstract][Full Text] [Related]
5. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients.
Kaduthanam S; Gade S; Meister M; Brase JC; Johannes M; Dienemann H; Warth A; Schnabel PA; Herth FJ; Sültmann H; Muley T; Kuner R
Lung Cancer; 2013 May; 80(2):223-7. PubMed ID: 23410826
[TBL] [Abstract][Full Text] [Related]
6. Plasma miR-1247-5p, miR-301b-3p and miR-105-5p as potential biomarkers for early diagnosis of non-small cell lung cancer.
Dong X; Chang M; Song X; Ding S; Xie L; Song X
Thorac Cancer; 2021 Feb; 12(4):539-548. PubMed ID: 33372399
[TBL] [Abstract][Full Text] [Related]
7. Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.
Fan L; Qi H; Teng J; Su B; Chen H; Wang C; Xia Q
Tumour Biol; 2016 Jun; 37(6):7777-84. PubMed ID: 26695145
[TBL] [Abstract][Full Text] [Related]
8. Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients.
Kumar S; Sharawat SK; Ali A; Gaur V; Malik PS; Kumar S; Mohan A; Guleria R
Curr Probl Cancer; 2020 Aug; 44(4):100540. PubMed ID: 32007320
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Serum Paired MicroRNA Ratios for Differential Diagnosis of Non-Small Cell Lung Cancer and Benign Pulmonary Diseases.
Fan L; Sha J; Teng J; Li D; Wang C; Xia Q; Chen H; Su B; Qi H
Mol Diagn Ther; 2018 Aug; 22(4):493-502. PubMed ID: 29922886
[TBL] [Abstract][Full Text] [Related]
10. Serum miR-339-3p as a potential diagnostic marker for non-small cell lung cancer.
Trakunram K; Chaniad P; Geater SL; Keeratichananont W; Chittithavorn V; Uttayamakul S; Buya S; Raungrut P; Thongsuksai P
Cancer Biol Med; 2020 Aug; 17(3):652-663. PubMed ID: 32944397
[No Abstract] [Full Text] [Related]
11. Clinical evaluation of microRNA expression profiling in non small cell lung cancer.
Markou A; Sourvinou I; Vorkas PA; Yousef GM; Lianidou E
Lung Cancer; 2013 Sep; 81(3):388-396. PubMed ID: 23756108
[TBL] [Abstract][Full Text] [Related]
12. Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells.
Jiang L; Huang Q; Zhang S; Zhang Q; Chang J; Qiu X; Wang E
BMC Cancer; 2010 Jun; 10():318. PubMed ID: 20569443
[TBL] [Abstract][Full Text] [Related]
13. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of lncRNA MIR503HG suppresses proliferation and promotes apoptosis of non-small cell lung cancer cells by regulating miR-489-3p and miR-625-5p.
Dao R; Wudu M; Hui L; Jiang J; Xu Y; Ren H; Qiu X
Pathol Res Pract; 2020 Mar; 216(3):152823. PubMed ID: 31983569
[TBL] [Abstract][Full Text] [Related]
15. Loss of MiR-424-3p, not miR-424-5p, confers chemoresistance through targeting YAP1 in non-small cell lung cancer.
Zhang M; Zeng J; Zhao Z; Liu Z
Mol Carcinog; 2017 Mar; 56(3):821-832. PubMed ID: 27500472
[TBL] [Abstract][Full Text] [Related]
16. Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer.
Tian F; Shen Y; Chen Z; Li R; Lu J; Ge Q
Gene; 2016 Oct; 591(2):338-43. PubMed ID: 27291819
[TBL] [Abstract][Full Text] [Related]
17. miR-30a-5p together with miR-210-3p as a promising biomarker for non-small cell lung cancer: A preliminary study.
Świtlik W; Karbownik MS; Suwalski M; Kozak J; Szemraj J
Cancer Biomark; 2018 Feb; 21(2):479-488. PubMed ID: 29103030
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of miR-125a-5p and let-7e predicts the progression and prognosis of non-small cell lung cancer.
Zhu WY; Luo B; An JY; He JY; Chen DD; Xu LY; Huang YY; Liu XG; Le HB; Zhang YK
Cancer Invest; 2014 Oct; 32(8):394-401. PubMed ID: 24945821
[TBL] [Abstract][Full Text] [Related]
19. miRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes.
Zhang YK; Zhu WY; He JY; Chen DD; Huang YY; Le HB; Liu XG
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1641-50. PubMed ID: 22618509
[TBL] [Abstract][Full Text] [Related]
20. High-throughput qRT-PCR validation of blood microRNAs in non-small cell lung cancer.
Leidinger P; Brefort T; Backes C; Krapp M; Galata V; Beier M; Kohlhaas J; Huwer H; Meese E; Keller A
Oncotarget; 2016 Jan; 7(4):4611-23. PubMed ID: 26672767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
